Oncothyreon Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Oncothyreon

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

From: Ron	6/2/2014 11:33:47 AM
	of 2344

Not sure how significant this is, but FYI ______________ Oncothyreon announces positive data from a Phase 1 trial of ONT-10 ( ONTY) : Co announces the presentation of data from a Phase 1 trial of ONT-10, an antigen-specific immunotherapy targeting MUC1, at the American Association of Clinical Oncology ( TATD) Annual Meeting. The data demonstrated that ONT-10 was well tolerated in this trial, resulted in a humoral immune response in the majority of patients and led to encouraging disease control in advanced stage patients with a variety of cancer types. "We are encouraged by the high percentage of patients who were able to enter the maintenance protocol and the lack of disease progression for at least 6 months seen in advanced stage patients...We believe these results support further development of ONT-10, and we are currently enrolling patients with advanced breast and ovarian cancer in two disease-specific expansion cohorts of this trial. We expect these patients to provide comparative data for the recently announced planned combination trial of ONT-10 with varlilumab, the fully human monoclonal antibody targeting CD27 from Celldex Therapeutics." finance.yahoo.com

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next